Avalo Therapeutics (AVTX) Accounts Payables (2014 - 2026)
Avalo Therapeutics posted quarterly Accounts Payables of $356000.0 for Q1 2026, down 47.72% year-on-year from $681000.0 in Q1 2025, and up 159.85% on a QoQ basis from $137000.0 in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Accounts Payables data on file, last reported at $356000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables fell 47.72% year-over-year to $356000.0; the trailing twelve-month figure through Mar 2026 stood at $356000.0 (down 47.72% YoY), and the FY2025 full-year result was $137000.0, down 51.59% from the prior year.
- Accounts Payables for Q1 2026 stood at $356000.0, up from $137000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $5.6 million in Q1 2023 and bottomed at $137000.0 in Q4 2025.
- The 5-year median for Accounts Payables is $789000.0 (2023), against an average of $1.5 million.
- The widest annual swing landed in 2023, when Accounts Payables sank 84.52%; it then jumped 261.77% in 2025.
- A 5-year view of Accounts Payables shows it stood at $2.9 million in 2022, then slumped by 84.52% to $446000.0 in 2023, then sank by 36.55% to $283000.0 in 2024, then sank by 51.59% to $137000.0 in 2025, then surged by 159.85% to $356000.0 in 2026.
- The last three Accounts Payables figures came in at $356000.0 (Q1 2026), $137000.0 (Q4 2025), and $474000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 356,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 356,000.00 |
| Dec 31, 2025 | 137,000.00 |
| Sep 30, 2025 | 474,000.00 |
| Jun 30, 2025 | 2.37 Mn |
| Mar 31, 2025 | 681,000.00 |
| Dec 31, 2024 | 283,000.00 |
| Sep 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 654,000.00 |
| Mar 31, 2024 | 916,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Sep 30, 2023 | 789,000.00 |
| Jun 30, 2023 | 751,000.00 |
| Mar 31, 2023 | 5.57 Mn |
| Dec 31, 2022 | 2.88 Mn |
| Sep 30, 2022 | 1.45 Mn |
| Jun 30, 2022 | 2.16 Mn |
| Mar 31, 2022 | 3.76 Mn |
| Dec 31, 2021 | 3.37 Mn |
| Sep 30, 2021 | 3.57 Mn |
| Jun 30, 2021 | 3.97 Mn |
| Mar 31, 2021 | 11.91 Mn |
| Dec 31, 2020 | 2.57 Mn |
| Sep 30, 2020 | 1.93 Mn |
| Jun 30, 2020 | 2.56 Mn |
| Mar 31, 2020 | 2.73 Mn |
| Dec 31, 2019 | 2.08 Mn |
| Sep 30, 2019 | 826,472.00 |
| Jun 30, 2019 | 1.45 Mn |
| Mar 31, 2019 | 1.25 Mn |
| Dec 31, 2018 | 1.45 Mn |
| Sep 30, 2018 | 1.54 Mn |
| Jun 30, 2018 | 2.94 Mn |
| Mar 31, 2018 | 3.17 Mn |
| Dec 31, 2017 | 1.30 Mn |
| Sep 30, 2017 | 312,514.00 |
| Jun 30, 2017 | 327,302.00 |
| Mar 31, 2017 | 595,876.00 |
| Dec 31, 2016 | 1.01 Mn |
| Sep 30, 2016 | 809,151.00 |
| Jun 30, 2016 | 756,464.00 |
| Mar 31, 2016 | 591,034.00 |
| Dec 31, 2015 | 678,109.00 |
| Sep 30, 2015 | 1.95 Mn |
| Dec 31, 2014 | 931,139.00 |